Announcements Trials
Browse Landscape

Phase

Phase 3 3Phase NA 1

Status

Completed 7Terminated 4Withdrawn 1

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Thoracic 3Plasma cell 1Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 3Recurrence 1Multiple Myeloma 1Breast Neoplasms 1

Interventions

pembrolizumab 184Carboplatin 130Paclitaxel 123Gemcitabine 122Docetaxel 96Cyclophosphamide 89Nivolumab 88Cisplatin 87Rituximab 71Dexamethasone 68Pemetrexed 64Bevacizumab 64Capecitabine 60atezolizumab 54fludarabine 49Azacitidine 49Fluorouracil 48130-nm albumin-bound paclitaxel 43venetoclax 41Trastuzumab 41Irinotecan 41Cetuximab 40Leucovorin 36Ipilimumab 36Erlotinib Hydrochloride 34Fulvestrant 32Cytarabine 32avelumab 31Oxaliplatin 31Albumin-Bound Paclitaxel 31

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Terminated × INDUSTRY × L-BLP25 × Clear all
NCT02049151 2017-08-23

START2

EMD Serono

Phase 3 Terminated
35 enrolled 10 charts
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT01015443 2016-10-26

INSPIRE

Merck KGaA, Darmstadt, Germany

Phase 3 Terminated
285 enrolled 12 charts
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT01423760 2016-10-06

Common Safety Follow-up Trial of Tecemotide (L-BLP25)

Merck KGaA, Darmstadt, Germany

Phase NA Terminated
27 enrolled 7 charts
Plasma cellThoracic

Carcinoma, Non-Small-Cell Lung, Multiple Myeloma

NCT00925548 2014-07-24

STRIDE

EMD Serono

Phase 3 Terminated
16 enrolled 6 charts
Breast

Breast Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡